All In Biotech

Drug Trial Radar · NCT05059106

EFFECTIVENESS, SAFETY AND IMMUNOGENICITY OF THE HALF DOSE OF THE VACCINE ChadOx1 nCoV-19 (AZD1222) for COVID-19

Last checked: Nov 20, 2026Latest source record: Sep 28, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

29,637

Planned (sponsor's estimate)

Start

Jun 1, 2021

Primary completion

Jun 1, 2022

Study completion Oct 30, 2022

Sponsor

Lead sponsor
Federal University of Espirito SantoAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Instituto René Rachou (IRR); Escola Nacional de Saúde Pública Sérgio Arouca/Fiocruz; Oswaldo Cruz Foundation; Escola Superior de Ciências da Santa Casa de Misericórdia de Vitória
First posted
Sep 28, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 49 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is clinical trial (intervention study with external comparison group) to test vaccination with reduced dose (half dose) of ChAdOx1 nCoV-19 (AZD1222), in a 2-dose schedule with an interval of 8 weeks, including all adults aged 18 to 49 years from Viana city - Espírito Santo (ES)/Brazil, on the incidence of new cases over 12 months following treatment, compared to an external group from same state and adjusted for socio-demographic and epidemiological variables.

Conditions

  • SARS-CoV-2

Interventions

  • Half dose of ChAdOx1 nCoV-19 (AZD1222)Biological

    Vaccination with reduced dose (half dose) of ChAdOx1 nCoV-19 (AZD1222), in a 2-dose schedule with an interval of 8 weeks, including all adults aged 18 to 49 years, from non-priority groups, from Viana city - Espírito Santo (ES)/Brazil.

  • Standard dose of ChAdOx1 nCoV-19 (AZD1222)Biological

    Vaccination with standad dose of ChAdOx1 nCoV-19 (AZD1222), in a 2-dose schedule with an interval of 8 weeks, in external cohort of health workers aged 18 to 49 years.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of new casesTime frame: 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Federal University of Espirito Santo

    Vitória, Espírito Santo, Brazil · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.